Pfizer Now Targeting Younger Kids For COVID Vaccine Approval

While the Biden administration continues to fall short of its stated vaccination goals at each and every deadline, at least one vaccine maker is now opening their product up to a new market: Children.

As schools around the nation return to in-person learning, fears of unvaccinated children spreading or falling ill with COVID continue to rise, especially as many of the vaccine makers have suggested that they’ve not yet approved their products for children.

All that changed on Monday, however, with a major announcement.

A smaller dose of Pfizer and BioNTech’s Covid-19 vaccine is safe and generates a “robust” immune response in a clinical trial of kids ages 5 to 11, the drugmakers announced Monday.

The news couldn’t come any sooner for parents anxious to get their children vaccinated as kids start the new school year with the delta variant surging across America. Children’s Covid cases remain disturbingly high with 243,000 new infections during the week ended Sept. 9. — the second-highest number of kids’ cases since the beginning of the pandemic, according to the most recent data from the American Academy of Pediatrics.

The data, which included more than 2,200 children, will be submitted to the Food and Drug Administration and other health regulators “as soon as possible,” the companies said. Pfizer CEO Albert Bourla said last week the company could submit data on children ages 5 to 11 by the end of this month. If the FDA spends as much time reviewing the data for that age group as it did for 12- to 15-year-olds, the shots could be available in time for Halloween.

Should the FDA follow suit with full approval for these children, there could be a major, heated debate about mandatory vaccinations for in-person learning on the horizon.

*The views and opinions expressed here are solely those of the author of the article and not necessarily shared or endorsed by*